

H Lundbeck A/S

Examples that are not biomarkers

- Rating scales (MADRS)
- PRO (patient reported outcomes)
- Tolerability
- Pain


ack Als


• Imaging interpretation (picture alone is a biomarker)

Surrogate endpoint definition A biomarker that is intended to substitute for a clinical endpoint. A surrogate endpoint is expected to predict clinical benefit (or harm or lack of benefit or harm) based on epidemiological, therapeutic,

pathophysiological, or other scientific evidence

10-Mor-11





Blood pressure


- Systolic and diastolic
- Supine or sitting


~ A/S


- White coat hypertension
- High measurement error
- Office versus 24h measurements


10.Mor.11


• EMA guideline (2010): 3 baseline visits; systolic primary; diastolic secondary; sufficient number of patients for mortality (1y); no suspicion of adverse target organ effect















Practical issues

- Timing: A diagnostic needs fast turnaround time
- Other: Inconvenience to patient; risk to patient; circadian variation (incl. meals); sex, age, weigth dependence; storage; stability; transportation; central lab.



10-Mor-11

ALS ANS

Clinical trials to qualify a Clinical trials to qualify a biomarker for monitoring biomarker as diagnostic • Example: For HbA1c, DCCT (1993) was the • Trial in relevant population (meaning turning point similar to the one where it will be • 1441 patients; stratified by retinopathy; applied) followed for up to 9 years; price-tag 1 bill. \$ • If multivariate diagnostic, formula • Intensified insulin treatment lead to both derivation should be pre-specified reduced HbA1c and reduced risk of • Evaluate sensitivity/specificity complications (vs. conventional therapy) compared to gold standard. Evaluate • Relation between post-treatment HbA1c and complications in intensive group AUC for ROC curve Lundbeck 10-Mar-11 10-Mar-11 H. Lundbeck A/S 25 H. Lundbeck A/S 26

Subject count	Diseased	Healthy	Vary the threshold between Bioma
Biomarker+	A	В	+ and – subgroups
Biomarker-	С	D	Combined values of sensitivity and
Sensitivity: A/(A+C); Specificity: D/(B+D) PPV: A/(A+B); NPV: D/(C+D) Odds ratio: A D / (B C)			 Evaluate performance by the AUC (more robust evaluation than select a single threshold)

Clinical trials to qualify a biomarker as predictive



- If multivariate biomarker, formula derivation should be pre-specified
- Positive subgroup effect checked according to standard practice (two adequate and well-controlled studies)
- Confirmed in later independent studies
- Negative subgroup effect checked, but potentially not as rigorous (interaction expected) depending on biological understanding

10.Mor.11

